Экспрессия сигнальных факторов дифференцировки фибробластов при старении и возраст-ассоциированных опухолях предстательной железы
Во всех случаях карцином простаты были обнаружены CXCL12/WEDC1 -продуцирующие фибробласты. Обширные и множественные скопления фибробластов в основном обнаруживались в высокодифференцированных опухолях. При этом опухолевые фибробласты не демонстрировали признаков пролиферативной активности. Площадь экспрессии протеина WEDC1 в раковых опухолях достоверно снижалась с увеличением возраста, в то время… Читать ещё >
Содержание
- ПЕРЕЧЕНЬ СОКРАЩЕНИЙ И УСЛОВНЫХ ОБОЗНАЧЕНИЙ
- ВВЕДЕНИЕ 5 ОБЗОР ЛИТЕРАТУРЫ
- Глава 1. СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О СТРУКТУРНО-ФУНКЦИОНАЛЬНОЙ ОРГАНИЗАЦИИ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ ПРИ СТАРЕНИИ И РАЗВИТИИ ГИПЕРПЛАСТИЧЕСКИХ ПРОЦЕССОВ, АССОЦИИРОВАННЫХ С ВОЗРАСТОМ
- 1. 1. Эмбриогенез и онтогенез предстательной железы человека
- 1. 2. Морфо-функциональная характеристика возрастных инволютивных изменений в предстательной железе
- 1. 3. Структурно-функциональная организация предстательной железы
- 1. 4. Нейроиммуноэндокринные фенотипы клеток предстательной железы
- 1. 5. Молекулярная биология гиперпластических процессов в предстательной железе, ассоциированных со старением
1.6. Роль фибробластов и их сигнальных молекул в механизмах возрастной инволюции простаты и развитии в ней гиперпластических процессов, ассоциированных со старением 47 РЕЗУЛЬТАТЫ СОБСТВЕННЫХ ИССЛЕДОВАНИЙ
Глава 2. МАТЕРИАЛ И МЕТОДЫ ИССЛЕДОВАНИЙ
2.1. Моделирование преждевременного старения животных
2.2. Изучение предстательной железы у человека
2.3. Гистологические и иммуногистохимические методы
2.4. Изучение эффектов действия пептидов на культивируемые фибробласты предстательной железы человека
2.5. Электронно-микроскопическое исследование
2.6. Морфометрические исследования
2.7. Статистическая обработка
Глава 3. ЭКСПРЕССИЯ СИГНАЛЬНЫХ ФАКТОРОВ ДИФФЕРЕНЦИРОВКИ ФИБРОБЛАСТОВ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ КРЫС В РАДИАЦИОННОЙ МОДЕЛИ ПРЕЖДЕВРЕМЕННОГО СТАРЕНИЯ
3.1. Контрольная группа
3.1. Опытная группа (модель преждевременного старения)
Глава 4. ЭКСПРЕССИЯ СИГНАЛЬНЫХ ФАКТОРОВ ДИФФЕРЕНЦИРОВКИ ФИБРОБЛАСТОВ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ ЧЕЛОВЕКА ПРИ ВОЗРАСТНЫХ ГИПЕРПЛАСТИЧЕСКИХ ПРОЦЕССАХ
4.1. Контрольная группа
4.2. Экспрессия сигнальных факторов дифференцировки фибробластов в предстательной железе человека при опухолевых процессах
4.2.1. Доброкачественная гиперплазия предстательной железы
4.2.2. Карцинома предстательной железы
Глава 5. ПЕПТИДЕРГИЧЕСКАЯ РЕГУЛЯЦИЯ ЭКСПРЕССИИ СИГНАЛЬНЫХ ФАКТОРОВ ДИФФЕРЕНЦИРОВКИ ФИБРОБЛАСТОВ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ ПРИ КЛЕТОЧНОМ СТАРЕНИИ 93 ОБСУЖДЕНИЕ РЕЗУЛЬТАТОВ ИССЛЕДОВАНИЯ
Глава 6. МОЛЕКУЛЯРНО-КЛЕТОЧНЫЕ МЕХАНИЗМЫ РЕГУЛЯЦИИ СТАРЕНИЯ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
ВЫВОДЫ
Список литературы
- Автандилов Г. Г. Медицинская морфометрия. Руководство. М.: Медицина, 1990. 384 с.
- Аль-Шукри С.Х., Корнеев И. А. Общие принципы лечения больных раком мочевого пузыря. Значение клинических, гистологических и биологических факторов прогноза для выбора метода лечения. // Практическая онкология. 2003. — Т.4. — № 4. — С. 204−211.
- Анисимов В.Н. Молекулярно-физиологические механизмы старения. В 2-х томах. СПб. Наука. — 2008. — 674 с.
- Анисимов В.Н., Арутюнян А. В., Хавинсон В. Х. Антиоксидантная роль эпиталамина и мелатонина // Геронтологические аспекты пептидной регуляции функций организма. СПб.: Наука, 1996. — С. 15.
- Анисимов В.Н., Кветной И. М., Комаров Ф. И., Малиновская Н. К., Рапопорт С. И. Мелатонин в физиологии и патологии желудочно-кишечного тракта. -М.: Советский спорт, 2000. 184 с.
- Анисимов В.Н., Рейтер Р. Функция эпифиза при раке и старении // Вопросы онкологии. 1990. — Т.36, №. 3.- С. 259−268.
- Анисимов В.Н., Хавинсон В. Х., Морозов В. Г. Эпифиз и рак // Успехи соврем, биол. 1980. — Т. 89, № 2. — С. 283−291.
- Аничков Н.М. Учение об апоптозе на современном этапе // Ученые записки СПбГМА им. И. И. Мечникова. 1999. — № 4. — С. 31−40.
- Аничков Н.М., Зиновьев А. С. Морфологические маркеры в диагностике опухолей. Изд-во Новосибирского университета. Новосибирск, 1993.- 131 с.
- Ю.Аничков Н. М., Кветной И. М., Коновалов С. С. Биология опухолевого ротса (молекулярно-медицинские аспекты). СПб. Прайм-Еврознак. — 2004. — 327 с.
- П.Берштейн JI.M. Эволюционная онкоэндокринология // Журнал эвол. биохим. и физиол. 2001. — Т. 37, № 5. — С. 446−449.
- Бондаренко JI.A. Современные представления о физиологии эпифиза // Нейрофизиология. 1997. — Т. 29, № 3. — С. 212−237.
- Дильман В.М. Эндокринологическая онкология. JL: Медицина, 1983. — 409 с.
- Зеленина Н.В., Марьянович А. Т., Цыган В. Н. Гуморальная регуляция апоптоза // В кн.: Программированная клеточная гибель. СПб.: Наука, 1996.-с. 89−103.
- Имянитов Е.Н., Хансон К. П. Эпидемиология и биология рака мочевого пузыря. // Практическая онкология. 2003. — Т.4. — № 4. — С. 191−195.
- Кветной И.М., Левин И. М. Мелатонин и опухолевый рост // Эксперим. онкология. 1986. — № 4. — С. 11−15.
- Кветной И.М., Райхлин Н. Т., Южаков В. В., Ингель И. Э. Экстрапинеальный мелатонин: место и роль в нейроэндокринной регуляции гомеостаза // Бюлл. эксперим. биол. мед. 1999. — Т. 127, № 4. — С. 364−370.
- Пальцев М.А., Кветной И. М. Руководство по нейроиммуноэндокринологии. -М. Медицина. 2006. — 368 с.
- Пальцев М.А., Кветной И. М. Руководство по нейроиммуноэндокринологии. М. Медицина. — 2008. — 576 с.
- Райхлин Н.Т., Кветной И. М., Дейнеко Г.М. APUD-система и эктопическая опухолевая продукция гормонов // Эксперим. онкол. -1983.-Т. 4.-С. 10−16.
- Райхлин Н.Т., Кветной И. М., Осадчук М.А. APUD-система (общепатологические и онкологические аспекты) // Обнинск, 1993. — С. 225.
- Романенко A.M., Носов А. Т., Базалицкая С. В. Изменения ядрышек и ядрышковых организаторов при пролиферативных циститах и переходноклеточном раке мочевого пузыря // Арх. патологии. — 1992. -Т. 54, № 7.-С. 14−19.
- Хавинсон В.Х., Морозов. В.Г., Малинин В. В. Пептидные тимомиметики.- СПб. Наука. — 2003 246 с.
- Хавинсон В.Х., Коновалов С. С. Избранные лекции по геронтологии.-СПб. Прайм-Еврознак. 2008. — 967 с.
- Цыган В.Н., Булавин Д. В., Марьянович А. Т., Пахомов Е. Ю. Роль апоптоза в патогенезе и лечении заболеваний // В кн.: Программированная клеточная гибель. СПб.: Наука, 1996. — С. 120 135.
- Abrahamsson P.-A. Neuroendocrine differention in prostatic carcinoma. The Prostate, 1999,39: 135−148.
- Abrahamsson PA, Cockett ATK, di SanfAgnese PA. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate Suppl. 1998: 8: 37−42.
- Abrahamsson PA, di SanfAgnese PA. Neuroendocrine cells inthe human prostate gland. J Androl 1993- 14: 307−309.
- Abrahamsson P-A, Falkmer S, Fait K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas: animmunohistochemical study testing chromogranin A as an «endocrine marker.» Pathol Res Pract 1989: 185: 373−380.
- Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L. Peptide-hormone- and serotonin-immunoreactive cells in carcinoma of the prostate. Pathol Res Pract 1987- 182: 298−307.
- Abrahamsson P-A. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate 1996- 6: 3−8.
- Abrahamsson P-A: neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate 1996- 6: 3−8
- Aiyar N, Rand K, Elshourbagy NA, Zeng ZZ, Adamou JE, Bergsma D, Li Yl. A cDNA encoding the calcitonin gene-related peptide type 1 receptor. J Biol Chem 1996- 271: 11 325−11 329.
- Alberti C. Hereditary/familial versus sporadic prostate cancer: few indisputable genetic differences and many similar clinicopathological features // Eur. Rev. Med. Pharmacol. Sci. 2010. — Vol. 14, N 1. — P. 31−41.
- Aldhous M.E., Arendt J. Radioimmunoassay for 6-Sulphatoxymelatonin in urine using an iodinated tracer // Clin. Biochem. 1988. — Vol. 25. — P. 296 303.
- Almagro UA, Tieu TM, Remeniuk E, Kueck R, Stumpf K. Argyrophilic, «carcinoid-like» prostatic carcinoma. Arch Pathol Lab Med 1986- 10: 916 919.
- Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997: 30: 1−6.
- Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjolnerod OK, Waldum HL. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 1997: 31: 110−117.
- Angelsen A, Waldum HL, Brenna E. Neuroendocrine differentiation in prostatic carcinoma letter. Hum Pathol 1995: 26: 1389.
- Anisimov V.N. The role of pineal gland in the breast cancer development // Crit. Rev. Oncol. Hematol. 2003. — Vol. 46, N 3. — P. 221−234.
- Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993: 71: 3952−3965.
- Arendt J. Human responses to light and melatonin // In: Advances in Pineal Research. London, 1994. — Vol. 8. — P. 439−441.
- Arendt J. Melatonin and Mammalian Pineal Gland // London: Chapman and Hall, 1995.-331 p.
- Arendt J., Bojkowski C., Franey C. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol // J. Clin Endocrinol Metab.- 1985. Vol. 60. — P. 1166— 1173.
- Aumuller G., Marcus L., Janssen M. Neurogenic origin of human prostate endocrine cells. Urology, 1999, 53: 1041−1048.
- Axelrod J., Weissbach H. Enzymatic O-methylation of N-acetyl-serotonin to melatonin //Science. 1960. — Vol. 131.-P. 1312−1318.
- Banerjee S., Margulis L. Mitotic arrest by melatonin // Exp. Cell Res. -1973.-Vol. 78.-P. 314−318.
- Barbosa P.F., Malafaia О., Ribas-Filho J.M., Czeczko N.G., Ribas C.M., Cuenca R.M., Chula D.C. Cytophotometric expression of tumor antigen markers Ki-67 and CD-34 in prostate adenocarcinoma // Rev. Col. Bras. Cir. 2009. — Vol. 36, N 6. — P. 498−503.
- Bartsch C., Bartsch H. Melatonin secretion in oncological patients: current results and methodological considerations // In: Adv. Pineal Res. Vol. 7. / Maestroni GJM, Conti A, Reiter RJ, eds.- London: John Libbey and Сотр., 1994.-P. 283—301.
- Bartsch C., Bartsch H. Significance of melatonin in malignant diseases // Wien Klin. Wochenschr. 1997. — Vol. 109. — P. 722−729.
- Bartsch C., Bartsch H., Bellmann O. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism // Cancer. 1991. — Vol. 67. — P. 1681−1684 .
- Bartsch C., Bartsch H., Fuchs U. Stage-dependent depression of melatonin in patients with primary breast cancer: correlation with prolactin, thyroid stimulating hormone and steroid receptors // Cancer. 1989. — Vol. 64. — P. 426—433.
- Bartsch C., Bartsch H., Karasek M. Melatonin in clinical oncology // Neuroendocrinol. Lett. 2002. — Vol. 236, Suppl. 1.- P. 30−38.
- Battaglia S., Casli A.M., Botticelli A.R. Age related distribution of the ndocrine cells in the human prostate: a quantitative study. Virchows Arch., A, 1994, 424:165−168.
- Bavik С., Coleman I., Dean J., et al. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation thtough paracrine mechanisms // Cancer Res., 2006. Vol. 66. N2. P. 794−802.
- Bilim V.N., Tomita Y., Kawasaki Т., Takeda M., Takahashi K. Variable Bcl-2 phenotype in benign and malignant lesions of urothelium. // Cancer Letters. 1998.-Vol. 128.-Nl.-P. 87−92.
- Blask D. E Melatonin biosynthesis, physiological effects, and clinical applications// In: Melatonin in oncology / Yu H.S., Reiter R.J. eds. Boca Raton: CRC Press, 1993. — P. 447−475.
- Blask D. E The pineal: an oncostatic gland? // The pineal gland / Reiter R.J. eds. New York: Raven Press, 1984. — P. 253—284.
- Blask D.E., Hill S.M. Melatonin and cancer: basis and clinical aspects // In: Melatonin. Clinical Perspectives / A. Miles, D.R.S. Philbrick eds. Oxford: Oxford Univ. Press, 1988. — P. 128−173.
- Blask D.E., Wilson S.T., Lemus-Wilson A.M. The oncostatic and oncomodulatory role of the pineal gland and melatonin // Advances in pineal research: Vol. 7 / Maestroni G.J.M., Conti A., Reiter R.J. eds. -London: John Libbey and Сотр., 1994. P. 235−241.
- Bojkowski C. J., Arendt A., Shih M.C., Markey S.P. Melatonin secretion in humans assessed by measuring 6-Sulfatoxymelatonin // Clin. Chem. 1987. -Vol. 33.-P. 1343−1348.
- Bologna M, Fesluccia C, Muzi P, Biordi L, Ciomeni M: Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989- 63: 1714−1720
- Bonkhoff H, Remberger К. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996: 28: 98−106.
- Bonkhoff H, Remberger K: Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: Stem cell model. Prostate 1996- 28: 98−106.
- Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Archiv A. 1993: 423: 291−294.
- Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 1995:26: 167−170.
- Bonkhoff H, Stein U, Remberger K: Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic and neoplastic human prostate. Virchows Arch A Pathol Anat 1993- 423: 291−294.
- Bonkhoff H, Stein U, Remberger K: End. ocrine-paracrine cell types in the prostate and prostatic adenocardnoma are postmitotic cells. Hum Pathol 1995,26: 167−170.
- Bonkhoff H, Stein U, Remberger K: Multidirectional differentiation in the normal, hyperplastic and neoplastic human prostate. Simultaneous demonstration of cell specific epithelial markers. Hum Pathol 1994- 25: 4246.
- Bonkhoff H, Stein U, Remberger K: The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994- 24: 224−118.
- Bonkhoff H, Stein U, Welter C, Remberger K. Differential expression of the PS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum Pathol 1995: 26: 824−828.
- Bonkhoff H, Stein. U, Aumuller G, Remberger K: Differential expression of aa-reductase isoenzymes in the human prostate and prostatic carcinoma. Prostate 1996- 29: 261−267.
- Bonkhoff H, Wemert N, Dhom G, Remberger K: Relation of endocrine-paracrme cells to cell proliferation in normal, hyperplastic and neoplastic human prostate. Prostate 1991- IS: 91−98.
- Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991: 19: 91−98.
- Bonkhoff H: Role of the basal cells in premalignant changes of the human prostate: A stem cell concept for the development of prostate cancer. Eur Urol 1996- 30- 201−205.
- Boran C., Kandirali E., Yilmaz F., Serin E., Akyol M. Reliability of the 34betaE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma // Urol. Oncol. 2010. — Vol. 24. — P. 112−118.
- Brzezinski A. Melatonin in humans // N Engl. J. Med. 1997. — Vol. 16.- P. 95−186.
- Bubendorf L, Sauter G, Moch H, Sckmid HP, Gasser TC, Jordan P, Mihatch MJ. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996: 178: 437 441.
- Callaghan B.D. Does the pineal gland have a role in the psychological mechanisms involved in the progression of cancer? // Med. Hypotheses. -2002. Vol. 59, N 3. — p> 302−311.
- Chalasani V., Macek P., O’Neill G.F., Barret W. Ureteric stricture secondary to unusual extension of prostatic adenocarcinoma // Can. J. Urol. 2010. -Vol. 17, N1.-P. 5031−5034.
- Cheifetz S, Hernandez H, Laiho M, ten Dijke P, Iwata KK, Massague J. Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellulai' responsiveness to three TGF-beta isoforms. J Biol Chem 1990: 265: 20 533−20 538.
- Cockett ATK, di SantAgnese PA, Gopinath P, Schoen SR, Abrahamsson PA. Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. Urology 1993: 42: 512−519.
- Cohen DW, Simak R, Fair WR, Melded J, Scher HI, Cordon-Cardo C. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostatic tissue. J Urol 1994: 152: 2120−2124.
- Cohen MK, Arber DA, Coffield S, Keegan GT, McClintock J, Speights VO. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994: 74: 1899−1903.
- Cohen P, Peehl D, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991: 73: 401−407.
- Cohen R, Glezerson 0, Haffejee Z: Neuroendocrine cells: A new prognostic parameter in prostate cancer. Br J Urol 1991- 68: 258−262.
- Cohen R., Glezerson G., Taylir L., Grundel H., Naude J. The neuroendocrine cell population of the human prostate gland. J. Urol., 1993, 150: 365−368.
- Cohen RJ, Glezerson G, Haffajee Z. Neuro-endocrine cells: a new prognostic parameter in prostate cancer. Br J Urol 1991: 68: 258−262.
- Cohen RJ, Glezerson G, Haffejee Z, Afrika D. Prostatic carcinoma: histological and immunohistological factors affecting prognosis. Br J Urol 1990- 66:405−410.
- Cohen RJ, Glezerson G. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer. Arch Pathol Lab Med 1992: 116: 65−66.
- Corpechat C, Baulieu E, Robel P. Testosteron, dihydrotestosterone and androstanediols in plasma, testes and prostates of rats during development Acta Endocrinogica 1981- 96: 127−135
- Cramer SC, Peehl DM, Edger MG, Wong ST, Deftos LJ, Feldman D: Parathyroid hormone-related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostade epithelial cells. Prostate 1996- 290: 20−29.
- Cunha G.R., Hayward S.W., Wang Y.Z., et al. Role of the stromal microenvironment in carcinogenesis of the prostate // Int. J. Cancer. 2003. Vol. 107. P. 1−10.
- Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, Foster BA. Normal and abnormal development of the male urogenital tract: role of androgens, mesenchymal-epithelial interactions and growth factors. J Androl 1992: 13: 465−475.
- Cunha GR, Foster B, Thompson A, Sugimura Y, Tanji-N, Tsuji M, Terada N, Finch PW, Donjacour AA. Growth factors as mediators of androgen action during the development of the male urogenital tract. World J Urol 1995: 13: 264−276.
- Cussenot 0, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, Meria P, Teillac P, Fiet J, Le Due A. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996: 155: 1340−1343.
- Dean J.P., Nelson P. S. Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis // British J. Cancer. 2008. Vol. 98. P. 245−249.
- Deftos LJ, Nakada S, Burton DW, di SanfAgnese PA, Cockett ATK, Abrahamsson PA. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996: 48: 58−62.
- Deftos LJ, Roos BA: Medullary thyroid carcinoma and calcitoningene expression. In Peck WA (ed): «Bone and Mineral Research.» New York: Elsevier, 1989, 267−316.
- Deftos LJ. Calcitonin. In: MJ Favus (ed): «Metabolism of Bone Diseases and Disorders of Mineral Metabolism,» New York: Lippincott-Raven Press, 1996, 82−91.
- Di Sant’Agnese F: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 1992- 70: 254−268.
- Duskova M., Hill M., Starka L. Changes of metabolic profile in men treated for androgenetic alopecia with 1 mg finasteride // Endocr. Regul. -2010.-Vol. 44, N 1. P. 3−8.
- Efstathiou J.A., Shipley W.U., Zietman A.L., Smith M.R. Hormonal therapies: ADT for prostate cancer: true love or heartbreak? // Nat. Rev. Clin. Oncol. 2010. — Vol. 7, N 3. — P. 130−132.
- English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989: 15: 233−250.
- Feyerter F: Uber das Helle-Zellen-System des menschen. Z. M. Krosk AnatForsch, 1951, 57: 324−344.
- Finch PW, Rubin JS, Miki A. Human KUF is FGF-related with properties of a p arac rine effecter of epithelial cells. Science 1989: 245: 752−755.
- Gittes KF: Carcinoma of the prostate. N Engl Med J 1991, 24: 236 245.
- Green D., Karpatkin S. Role of thrombin as a tumor growth factor // Cell Cycle. 2010. — Vol. 9, N 4. — P. 49−55.
- Grignon D, Caplan R, Sakr W, Porter A, Doggen RLS, John M, Abrams R, Lawton C: Neuroendocrine (NE) differentiation as prognostic indicator in locally advanced prostate cancer (PCa). Lab. Invest 1995- 72: 76A.
- Habib FK. The role of growth factors in the pathogenesis of BPH. Prog Clin Biol Res 1994: 386: 43−50.
- Hamada Y, Oishi A, Shoji T, Takada H, Yamamura M, Hioki K, Yamamoto M. Endocrine cells and prognosis in patients with colorectal carcinoma. Cancer 1992: 69: 2641−2646.
- Hermanek P., Sobin L.H. Classification of malignant tumours. -Berlin: Springer-Verlag, 1992.
- Hockenbery DM, Zutter M, Hickey W, Moon N, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991: 88: 6961−6965.
- Hoosein N, Abdul M, McCabe R, Gero A, Deftos L, Banks M, Hodges S, Finn L, Logothetis C. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol Oncol 1995: 1: 246−251.
- Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995: 147: 386−396.
- Hutter WB, Gerdes H-H, Rosa P. The granin (chromogranin/secretogranin) family. TIBS 1991- 16:27−30
- Inan N., Fayda M., Aksu G., Akansel G., Muezzinoglu В., Arslan A. Leiomyoma of the seminal vesicle mimicking tumoral extension of prostatic carcinoma // Acta. Chir. Belg. 2009. — Vol. 109, N 6. — P. 811−814.
- Isaacs JT, Furuya Y, Berges R The rate of androgens in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Seminars in Cancer Biology 1994- 5: 391−400
- Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett ATK, Deftos LJ: Parathyroid honnone-related protein: A potential autocrine growth factor in human prostate cancer cell lines. Urology 1994- 43: 675−679.
- Iwamura M, Geshagen S, Lapets 0, Moynes R, Abrahamsson PA, Cockett ATK, Deftos LJ, di SanfAgnese PA. Immunohistochemical localization of parathyroid hormone-related protein in prostatic intraepithelial neoplasia. Hum Pathol 1995: 26: 797−801.
- Iwamura M, Wu G, Abrahamsson PA, Cockett A, Foss K, Deftos L: Parathyroid hormone-related protein: A potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994- 43: 675−679.
- Iwamura M, Wu G, Abrahamsson PA, di Sant' Agnese P, Cock-ett ATK, Deftos LJ: Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 1994- 43: 667−674.
- Jakowlew SB, Dillard PJ, Kondaiah P, Sporn MB, Roberts AB. Complimentary deoxyribo-nucleic acid from chick embryo chondrocytes. Mol Endocrinol 1988: 2: 747−755.
- Jelbart ME, Russell PJ, Russell P, Wass J, Fullerton M, Wills EJ. Site-specific growth of the prostate xenograft line UCRY-PR-2. Prostate 1989- 14: 163−175.
- Kadmon D, Thompson T, Lynch G, Scardino P. Elevated plasma chromogranin A concentrations in prostatic carcinoma. J Urol 1991: 146: 358−361.
- Kazzaz В A. Argentaffin and argyrophil cells in the prostate J. Pathol 1974: 112:189−193
- Kim 1Y, Ahn HJ, Zelner DJ, Park L, Sensiber JA, Lee C. Expression and localization of transforming growth factor beta type I and II receptors in the rat ventral prostate during regression. Mol Endocrinol 1996: 10: 107−115.
- Kimura N, Hoshi S, Takahashi M, Takeha S, Shizawa S, Nagura H. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol 1997: 157: 565−568.
- Kondaiah P, Sands MJ, Smith JM, Fields A, Roberts AB, Spora MB, Melton DA. Identification of a novel transforming growth factor-13 (TGF-B5) mRNA in Xenopus laevis. J Biol Chem 1990: 265: 10 891 093.
- Krijnen J, Janssen P, Ruizeveld de Winter JA, van Kimpen H, Schroder F, van der Kwast T: Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993- 100: 393−398.
- Krijnen JLM, Janssen PJA, Ruizeveld de Winter JA, van Krimpen H, Schroder FH, van der Kwast TH. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993: 100: 393−398.
- Kvetnoy I.M. Extrapineal melatonin in pathology: new perspectives for diagnosis, prognosis and treatment of illness // Neuroendocrinolog. Lett. 2002. — Vol. 23, Suppl. 1. — P. 92−96.
- Kvetnoy I.M., Sandvik A.K., Waldum H.L. The diffuse neuroendocrine system and extrapineal melatonin // J. Mol. Endocrinol. -1997. Vol. 18. — P. 1−3.
- Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990: 50: 3748−3753.
- Kyprianou N, Isaacs JT. Expression of transforming growth factor-(B in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989: 3: 1515−1522.
- Kyprianov N, Isaacs JT. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989: 3: 1515−1522.
- Lapin V. Pineal gland and malignancy // Oster. Zeitschrift fur Oncologie .- 1976. Vol. 3. — P. 51−60.
- Lauder JM, Tamir H, Sadler TW. Serotonin and morphogenesis: sites of 5-HT uptake and binding protein: immunoreactivity in the midgestation mouse embryo. Development 1988- 102: 709−720
- Lee DC, Rochford RM, Todaro GJ, Villareal LP (1985): Developmental expression of rat transforming growth factor-a mRNA. Mol Cell Biol 5: 3644−3646.
- Lee Y.C., Cheng C.J., Huang M., Bilen M.A., Ye X., Navone N.M., Chu К., Kao H.H., Yu-Lee L.Y., Wang Z., Lin S.H. Androgen depletion up-regulates cadherin-11 expression in prostate cancer // J. Pathol. 2010. -Vol. 5. — P. 10−21.
- Lerner A., Case J., Takahashi J. Isolation of melatonin, the pineal gland factor that lightens melanocytes // J.Amer. Chem. Soc. -1958. Vol. 81. — P. 6084−6086.
- Lin Z., Kim H., Park H., Kim Y., Cheon J., Kim I. The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium. // Urol. Res. -2003. Vol. 31. -N4. — P. 272−275.
- Lipponen P.K., Aaltomaa S., Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumours. // Histopathology. 1996.- Vol. 28.-N2.-P. 135−140.
- Lissoni P., Barni S., Crispino S. Endocrine and immune effects of melatonin therapy in metastatic cancer patients // Eur. J. Cancer Clin. Oncol. 1989.-Vol. 25.-P. 789−795.
- Lu Q.L., Laniado M., Abel P.D., Stamp G.W., Lalani E.N. Expression of bcl-2 in bladder neoplasms is a cell lineage associated and p53-independent event. // Mol. Pathol. 1997. — Vol. 50. -Nl. — P. 28−33.
- Lum A.M., Wang B.B., Beck-Engeser G.B., Li L., Channa N., Wabl M. Orphan receptor GPR110, an oncogene overexpressed in lung and prostate cancer // BMC Cancer. 2010. — Vol. 10, N 1. — P. 40.
- Marcu M., Radu E., Sajin M. Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance // Rom .J. Morphol. Embryol. 2010. — Vol. 51, N 1. — P. 7−12.
- Marcu M., Radu E., Sajin M. Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance // Rom. J. Morphol. Embryol. 2010. — Vol. — 51, N 1. — P. 7−12.
- Marlin E.S., Hyams E.S., Dulabon L., Shah O. Metastatic esophageal adenocarcinoma to the prostate presenting with bilateral ureteral obstruction //Can. J.Urol.-2010.-Vol. 17, N l.-P. 5035−5037.
- Massague J, Cheifetz S, Boyd FT, Andres JL TGF-beta receptors and TGF-beta binding proteoglycans: recent progress in identifying their functional properties. Ann NY Acad Sci 1990: 593: 59−72.
- Massague J. The TGF-13 family of growth and differentiation factors. 1987: Cell 49: 437−438.
- Matsuda Т., Saika K. Comparison of Time Trends in Prostate Cancer Mortality (1990−2006) in the World, from the WHO Mortality Database // Jpn. J. Clin. Oncol. 2010. — Vol. 40, N 3. — P. 279−280.
- McNeal J.E. Normal histology of the prostate. Am. J. Surg. Pathol., 1988, 12(8): 619−33.
- Mc William LJ, Manson С, George NJR. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 1997: 80: 287−290.
- Modigliani E, Alamowitch C, Cohen R, Calmettes C, Guliana JM, Franc B, Bernard C, Chyvialle JA. The intratumoral immunoassayable somatostatin concentration is frequently elevatedin medullary thyroid carcinoma. Cancer 1990: 65: 224−228.
- Moseley JM, Martin TJ: PTHrP: Physiological actions. In Bilezikian JP, Raisy LG, Rodan GA (eds): «Principles of Bone Biology.» San Diego: Academic Press, 1996.
- Nakada SY, di Sant Agnese PA, Moynes RA, Hiipakka RA, Liao S, Cockett ATK, Abrahamsson PA. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 1993: 53: 1967−1970.
- Nemeth JA, Sansibar JA, White RR, Zelner DJ, Kim IY, Lee C. Prostatic duetai system in rats: tissue-specific expression and regional variation in stremai distribution of transforming growth factor-pi. Prostate 1997:33: 64−71.
- Nishi N, Oya H, Matsumoto K, Nakamura T, Miyanaka H, Wada F Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates. Prostate 1996- 28: 139−152.
- Njiaju U.O., Truica C.I. Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report // Clin. Breast Cancer. 2010. — Vol. 10, N 1. — P. 3−5.
- Paul R, Chang P, di SanfAgnese PA, Cockett ATK, Abrahamsson PA. Prognostic significance of neuroendocrine differentiation in human benign prostate and prostatic carcinoma. J Urol 1993: 149: 480.
- Pawlikowski M., Winczyk K., Karasek M. Oncostatic action of melatonin: facts and question marks // Neuroendocrinol. Lett. 2002. — Vol. 23, Suppl. 1. — P. 24−29.
- Pearse A.G.E. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J. Histochem Cytochem., 1969, 17: 303−313.
- Pearse A.G.E. The diffuse neuroendocrine system and the APUD concept. Med. Biol. 1977, 55: 149−156.
- Peehl DM, Edgar MG, Cramer SD, Deftos LJ: Parathyroid hormone-related protein (PTHrP) is not an autocrine growth factorfor normal prostatic epithelial cells. Prostate 1996- 29: 6−10.
- Peehl DM, Wong S, Bazinet M, Stamey ТА In vitro studies human prostatic epithelial cells: attempts to identify distinguishing features of malignant cells. Growth Factors 1989- 1: 237−250.
- Peehl DM, Wong ST, Rubin JS. KGF and EGF differentially regulate thephenotype of prostatic epithelial cells. Growth Regul 1996: 6: 22−31.
- Pisters LL, Trencoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW. c-met protooncogene expression in benign and malignant human prostate tissues. J Urol 1995: 154: 293−298.
- Poeggeler В., Reiter R.J., Tan D-X., Chen L-D., Manchester L.C. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: A hypothesis // J. Pineal Res. 1993. — Vol. 14. — P. 151−168.
- Power RF, Mani SK, Codina J, Connely OM, Malley BW. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 1991: 254: 1636−1639.
- Pretl K. Zur Frage der Endokrinie der menschlichen Vorsteherdruse. Virchows Arch., A, 1944- 312: 392−404.
- Raikhlin N.T., Kvetnoy I.M. The APUD system (diffuse endocrine system) in normal and pathological states // Physiol. Gen. Biol. Rev. 1994. -Vol. 8, N4.-P. 1−44.
- Rappolee DA, Brenner CA, Schultz R, Mark D, Werb Z Developmental expression of PDGF, TGF-alpha, and TGF-J3 genes in preimplantation mouse embryos. Science 1988- 241:1823−1825.
- Regelson W., Pierpaoli W. Melatonin: a rediscovered antitumor hormone // Cancer Invest. 1987. — Vol. 5. — P. 276−283.
- Reiter R.J. Free radicals, melatonin, and cellular antioxidative defense mechanisms // In: Pathophysiology of Immune-Neuroendocrine Communication Circuit / D. Gupta, H.A. Wollmann, P.G. Fedor-Fregbergh, eds. Stuttgart: Mattes Verlag. — 135−160.
- Reiter R.J. Melatonin: that ubiquitously acting pineal hormone // News Physiol Sci. 1991. — Vol 6. — P. 223−227.
- Reiter R.J. Melatonin: clinical relevance // Best Pract. Res. Clin. Endocrinol. Metab. 2003. — Vol. 17, N 2. — P. 273−285.
- Reiter R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interaction // Endocr. Rev. 1991. — Vol. 12. — P. 80−151.
- Reiter R.J., Poeggeler В., Tan D.X. et al. Antioxidant capacity of melatonin: a novel action not requiring a receptor // Neuroendocrinol. Lett. -1993.-Vol. 15, N 1−2.-P. 103−116.
- Reiter R.J., Tan D.X., Cabrera J., D’Arpa D., Sainz R.M., Mayo J.C., Ramos S. The oxidant/antioxidant network: role of melatonin // Biol. Signals Recept 1999. — Vol. 8. — P. 56−63.
- Ritchie CK, Thomas KG, Andrews LR, Tindall DJ, Fitzpatrick LA. Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 1997- 30: 183−187.
- Rosa P, Gerdes HH: The granin protein family: Markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors. J Endocrinol Invest 1994- 17: 207−225.
- Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL. Evidence that insulin-like growth factor 1 and growth hormone are required for prostate gland development. Endocrinology 1999: 140: 1984−1989.
- Russell J, Gee P, Liu SM. Angeletti RH. Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. Endocrinology 1994- 135:337−342
- Russell PJ, Bennett S, Strieker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998: 44: 705−723.
- Sauer L., Gitenay D., Vo C., Baron V.T. Mutant p53 initiates a feedback loop that involves Egr-l/EGF receptor/ERK in prostate cancer cells // Oncogene. 2010. — Vol. 15. — P. 18−26.
- Schuurmans AL, Bolt J, Mulder E. Androgens and transforming growth factor beta modulate the growth response to epidermal growth factorin human prostatic tumor cells (LNCaP). Mol Cell Endocrinol 1988: 60: 101−104.
- Segal NH, Cohen RJ, Haffejee Z, Savage N. BCL-2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 1994: 118:616−618.
- Segre CV: Receptors for PTH and PTHrPR. In Bilezikian JP, Raisy LG, Rodan GA (eds): «Principles of Bone Biology.» San Diego: Academic Press, 1996.
- Seuwen K, Pouyssegur J. Serotonin as a growth factor.Biochem. Pharmacol. 1990- 39: 985−990
- Shiina H., Igawa M., Urakami S., Honda S., Shirakawa H., Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. // J. Clin. Pathol. 1996. — Vol. 49. — N5. — P. 395−399.
- Shirakawa H., Kozakai N., Sugiura H., Hara S. Urinary bladder metastasis of prostate cancer: a case report // Hinyokika Kiyo. 2010. — Vol. 56, N2. — P. 123−125.
- Silvestroni L, Menditto A, Frajesse G, Gnessi L: Identification of CT receptors in human spermatozoa. J Clin Endocrinol Metab 1987- 5: 742−746.
- Sim SJ, Glassman AB, RO JY, Lee JJ, Logothetis CJ: Serum calcitonin in small cell carcinoma of the prostate. ACLS 1996- 20: 487 491.
- Singh S., Singh U., Grizzle W., et al. CXCL12-CXCR4 interactions modulate prostate' cancer cell migration, metalloproteinase expression and invasion//Lab. Invest. 2004. Vol. 84. P. 1666−1676.
- Sjoberg HE, Arver S, Bucht E. High concentration of immunoreactive calcitonin of prostatic origin in human semen. Acta Physiol Scand 1980- 110: 101−102.
- Sjoberg HE, Arver S, Butcht E: High concentration of immunoreactive calcitonin of the prostatic origin in human semen. Acta Physiol Scand 1980- 110:101−102
- Song Y.S., Song Y., Luo J.Y., Wu B. Diagnosis and treatment of coincident vesical transitional cell carcinoma and prostate cancer: a report of 5 cases // Zhonghua Nan Ke Xue. 2010. — Vol. 16, N 1. — P. 44−47.
- St Amaud R, Poyet P, Walker P, Labrie F Androgen modulate epidermal growth factor expression in the rat ventral prostate. Mol Cell Endocrinol 1988- 56: 21−27.
- Stiles CD, Capone G, Scher CD, Antoniades HN, Van Wyk JJ, Pledger WJ. Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci USA 1979: 76:1279−1283
- Story MT, Hopp KA, Meier D. Regulation of basic fibroblast growth factor expression by transforming growth factor in cultured human prostate stroma cells. Prostate 1996: 28 :219−226
- Story MT, Норр КА, Molter М, Meier DA. Characteristics of FGF-receptors expressed by stromal and epithelial cells cultured from normal and hyperplastic prostates. Growth Factors 1992: 10: 269−280.
- Swift S.L., Bums J.E., Maitland N.J. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer // Cancer Res. 2010. — Vol. 70, N 1. — P. 347−356.
- Tanfi N, Tsuji M, Ierada N, Takeuchi M, Cunha GR. Inhibitory effects of transforming growth factor-p on androgen-induced development of neonatal mouse seminal vesicles in vitro. Endocrinology 1994: 134: 11 551 162.
- Tarle M, Rados N. Investigation on serum neuron-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay. Prostate 1991: 19: 23−33.
- Taylor ТВ. Ramsdell JS. Transforming growth factor-alpha and its receptor are expressed in the epithelium of the rat prostate gland. Endocrinology 1993: 133: 1306−1311.
- Tenniswood MP, Guenette RS, Lakins J, Mooibroek M, Wong P, Welsh J-E. Active cell death in hormone-dependent tissues. Cancer Metastasis Rev 1992- 11: 197−220.
- Tetu В, Ro JY, Ayala AG, Johnson DE, Logothetis С J, Ordonez NG. Small cell carcinoma of the prostate: Part I. A clinicopathologic study of 20 cases. Cancer 1987: 59: 1803−1809.
- Timme TL, Truong LD, Slavin KM, Kadmon D, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth. Microsc Res Tech 1995: 30: 333−341.
- Tinajero JC, Fabbri A, Dufau ML. Regulation of corticotropin-releasing factor secretion from Leydig cells by 5-HT. Endocrinology 1992- 130: 1780−1787
- Tindall E.A., Hoang H.N., Southey M.C., English D.R., Hopper J.L., Giles G.G., Severi G., Hayes V.M. The 4q27 locus and familial prostate cancer risk// BMC Cancer. 2010. — Vol. 10, N 1. — P. 69.
- Tolle A., Abdallah Z., Jung K., Baumler H. Measurement Conditions for Flow Cytometry Analyses of Cell Lines from Urological Carcinomas // J. Fluoresc. 2010. — Vol. 29. — P. 101−106.
- Traish AM. Wotiz HH Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology 1987- 121: 1461−1490.
- Vargas SJ, Gillespie MT, Powel GJ, Southby J, Danks JA, Mosely MJ, Martin TJ. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesion by in situ hybridization. J Bone Miner Res 1992: 7: 971−979.
- Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Falotie A, Tammela T, Isola J, Kallionienii OP: In vivo amplification of the androgen receptor gene and progresssion of human prostate cancer. Nature Genet 1995- 9: 401−406.
- Weinstein MH, Partin AW, Veltri RW, Epstein .I: Neuroendocrine differentiation, in prostate cancer: Enhanced prediction of progession after radical prostatectomy. Hum Pathol 1996- 27: 683−687.
- Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996: 27: 683−687.
- Winkler ME, O’Conner L, Winget M, Fendly B. Epidermal growth factor and transforming growth factor a bind differently to the epidermal growth factor receptor. Biochemistry 1989: 28: 6373−6378.
- Wong YC, Wang YZ. Growth factors and epithelial-stromal interactions in prostate cancer development. Int Rev Cytol 2000: 199: 65 116.
- Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994: 370:341−347.
- Wu G, Burzon DT, di Sant' Agnese PA, Schoen S, Leisenring A, Deftos LJ, Gershagen S, Cockett ATK: Calcitonin receptor mRNA expression in the human prostate. Urology 1996- 47: 376−381.
- Yamagushi A, Ishida T, Nishimura G, Kumaki T, Katoh M, K’Osaka T, Yonemura Y, Miyazaki I. Human chorionic gonadotropin in colorectal cancer and its relationship to prognosis'. Br J Cancer 1989: 60: 382−384.
- Yan SD, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL. Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. Mol Endocrinol 1992: 6: 2123−2128.
- Yang KH, Stewart AF. PTHrP: The gene, its mRNA species, and protein products. In Bilezikian JP, Raisy LG, Rodan GA (eds): «Principles of Bone Biology.» San Diego: Academic Press, 1996.
- Yong X., Smedts F., Verholfstad A. Cell kinetics of the prostate exocrine and neuroendocrine epithelium and their differential interrelationship. In: New perspectives of the prostate, 1998, Suppl. 8:62−73.
- Zhang Т., Zhang X., Ding K., Yang 1С., Zhang Z., Xu Y. PIM-1 gene RNA interference induces growth inhibition and apoptosis of prostate cancer cells and suppresses tumor progression in vivo // J. Surg. Oncol. 2010. -Vol. 11. — P. 25−31.
- Zifa E, Fillion G.5-hydroxytryptamine receptors: Pharmacol Rev 1992- 44: 401−458e